The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
Avatrombopag is a cost-effective treatment compared with romiplostim and eltrombopag for the second-line treatment of adults with ITP from the perspective of the UK NHS.
Authors
- Nichola Cooper (ORCID: https://orcid.org/0000-0002-9845-8292)
- Daniel Eriksson (ORCID: https://orcid.org/0000-0001-7699-242X)
- Carly Rich (ORCID: https://orcid.org/0000-0003-4717-5855)
- Mondher Toumi (ORCID: https://orcid.org/0000-0001-7939-7204)
- Michał Pochopień
- Sı́lvia Stanisçuaski Guterres (ORCID: https://orcid.org/0000-0002-6085-6826)
- Anna Tytuła
- Sian James (ORCID: https://orcid.org/0000-0002-8597-9179)
- Koo Wilson
Institutions
- Aix-Marseille Université (FR)
- Swedish Orphan Biovitrum (Sweden) (SE)
- Imperial College London (GB)
Publication Details
- Journal
- Journal of Market Access & Health Policy
- Published
- 2025-03-24
- DOI
- https://doi.org/10.3390/jmahp13020011
- Citations
- 3
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31